A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease

Drug Interactions With Direct-Acting Antivirals for Hepatitis C

(2015) Sarah Burgess et al.   ANNALS OF PHARMACOTHERAPY

Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment

(2015) Tushar Garimella et al.   ANTIVIRAL THERAPY

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir

(2015) Brian J. Kirby et al.   CLINICAL PHARMACOKINETICS

LP02 : C-surfer: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease

(2015) D. Roth et al.   JOURNAL OF HEPATOLOGY

LP08 : Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: Real-world experience from HCV-target

(2015) V. Saxena et al.   JOURNAL OF HEPATOLOGY

P0802 : Safety and efficacy of sofosbuvir + simeprevir without ribavirin in hepatitis C genotype 1-infected patients with end-stage renal disease or GFR

(2015) H.E. Nazario et al.   JOURNAL OF HEPATOLOGY

LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study

(2015) P.J. Pockros et al.   JOURNAL OF HEPATOLOGY

Daclatasvir + Asunaprevir: First Global Approval

(2014) Raewyn M. Poole   DRUGS

Safety, Tolerability, and Pharmacokinetics of Ribavirin in Hepatitis C Virus-Infected Patients with Various Degrees of Renal Impairment

(2013) B. J. Brennan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment of chronic hepatitis C in hemodialysis patients

(2008) Marina Berenguer   HEPATOLOGY